Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocugen, Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing modifier gene therapies for retinal diseases. Form 8-K disclosures cover clinical and Regulation FD updates for programs including OCU410, capital-structure events such as warrant exercises and 6.75% convertible senior notes due 2034, and material agreements tied to the note indenture and loan repayment.
Proxy materials describe annual meeting proposals, shareholder voting matters, and governance practices. Other filings identify the company's common stock on The Nasdaq Capital Market, preliminary financial information, authorized-share validation matters, and furnished investor presentations containing forward-looking clinical-development statements.
Ocugen, Inc. reported positive 12‑month topline Phase 2 ArMaDa data for OCU410, its modifier gene therapy for geographic atrophy secondary to dry age‑related macular degeneration. The optimal medium dose showed a 31% reduction in GA lesion growth versus control at 12 months and a 27% slower loss of the ellipsoid zone, a structural marker linked to visual function. Across treated patients there were no OCU410‑related serious adverse events or adverse events of special interest, supporting a favorable safety and tolerability profile. Based on these results, Ocugen plans to initiate a global Phase 3 registrational trial of OCU410 with up to 300 subjects in the third quarter of 2026, as part of its broader goal of three biologics license applications in three years.
Ocugen, Inc. reports that an institutional investor partially exercised previously issued warrants and purchased 10,000,000 shares of common stock on March 12, 2026. This warrant exercise generated gross proceeds of $15.0 million for Ocugen. The company states that, based on this cash infusion, it now anticipates its cash runway will extend into the first quarter of 2027, supporting ongoing operations and development plans.
Ocugen, Inc. Chief Financial Officer Treerita Essalima Johnson-Greene filed an initial statement of beneficial ownership. The filing reports 750,000 options to buy Ocugen stock and 500,000 common shares held directly, plus 350 common shares held indirectly by a spouse.
The reported option vests in equal annual installments over three years beginning on February 17, 2027, subject to continued service with the company on each vesting date. This filing establishes the CFO’s starting equity position as a reporting insider.
Ocugen, Inc. is a late-stage biotechnology company focused on gene therapies and biologics for serious eye diseases, a regenerative knee cartilage implant, and an inhaled mucosal vaccine platform. Its lead modifier gene therapy, OCU400 for retinitis pigmentosa, has completed Phase 3 enrollment of 140 subjects, with a rolling BLA planned to begin in the third quarter of 2026 and topline data expected in the first quarter of 2027. Long-term Phase 1/2 data show approximately 2-line LLVA gains and durable safety across multiple mutations.
OCU410 and OCU410ST, both based on the RORA gene, target geographic atrophy and Stargardt disease, respectively. Phase 2 ArMaDa data for OCU410 showed a 46% reduction in lesion growth at 12 months versus control and a favorable safety profile, while Phase 1 GARDian1 data for OCU410ST showed atrophic lesion growth 54% slower at 12 months in treated eyes and 100% stabilization or improvement in visual function among evaluable treated eyes. A 51-patient Phase 2/3 pivotal trial for OCU410ST is underway, with enrollment expected to complete in early 2026 and a BLA submission planned in the first half of 2027.
The company is also developing OCU200, a fusion protein for DME, DR, and wet AMD now in a multicenter Phase 1 trial, and NeoCart, a Phase 3-ready autologous knee cartilage implant held in its OrthoCellix subsidiary. Its inhaled COVID-19 vaccine candidate OCU500 will enter a Phase 1 trial funded by NIAID’s Project NextGen, and Ocugen reports 80 patents and 66 pending applications worldwide supporting its pipeline and partnered programs.
Ocugen, Inc. has filed an 8-K describing a petition to the Delaware Court of Chancery under Section 205 of the Delaware General Corporation Law. The company asks the court to validate a charter amendment that increased authorized common shares from 295,000,000 to 390,000,000 and to confirm the validity of shares issued based on that change.
The petition follows a stockholder lawsuit challenging whether special Series C preferred stock could vote on the 2024 share increase proposal. Ocugen states it acted in good faith, that a correction filing fixed any drafting issue, and that about 33,009,874 shares have been issued in reliance on the amendment. A hearing on the petition is scheduled for May 6, 2026, and the stockholder plaintiff does not oppose the requested relief.
Ocugen, Inc. reported fourth quarter and full year 2025 results and a broad business update focused on its gene therapy pipeline. For 2025, total revenue was $4,413 thousand while operating expenses reached $67,329 thousand, leading to a net loss of $67,846 thousand, wider than 2024. Cash, cash equivalents and restricted cash fell to roughly the high teens in millions of dollars, and total stockholders’ equity turned negative.
Clinically, enrollment is complete in the 140-patient Phase 3 liMeliGhT trial of OCU400 for retinitis pigmentosa, with topline data planned in the first quarter of 2027 to support a Biologics License Application. OCU410 for geographic atrophy showed preliminary Phase 2 results including a 46% reduction in lesion growth versus control at 12 months and a 60% slower rate of ellipsoid zone loss in treated eyes. Management is targeting three BLA submissions for OCU400, OCU410ST and OCU410 between 2026 and 2028. To bolster liquidity, Ocugen completed a $22.5 million underwritten registered direct offering in January 2026 and notes it may receive up to an additional $30 million if previously issued warrants are exercised, which together underpin guidance for a cash runway into at least the fourth quarter of 2026.
Ocugen, Inc. appointed Rita Johnson-Greene as Chief Financial Officer effective February 9, 2026, with her role as principal financial officer beginning after the filing of the Annual Report for the year ended December 31, 2025. Current principal financial officer Ramesh Ramachandran will continue as Chief Accounting Officer and principal accounting officer.
Under her employment agreement, Ms. Johnson-Greene will receive a $440,000 annual base salary, an initial target bonus opportunity of up to 45% of base salary, and a $90,000 sign-on bonus subject to repayment if she departs within one year. She was granted options to purchase 750,000 shares of common stock and 500,000 restricted stock units that vest in equal annual installments over three years. The agreement includes 12 months of salary continuation and COBRA premium support upon certain terminations, with additional bonus and full equity vesting acceleration if such a termination occurs around a change in control.
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Ocugen Inc. common stock. Vanguard reports beneficial ownership of 16,475,562 shares, representing 5.27% of the class as of 12/31/2025.
Vanguard has shared voting power over 1,981,345 shares and shared dispositive power over 16,475,562 shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of influencing control of Ocugen.
Ocugen, Inc. completed its previously announced underwritten offering of 15,000,000 shares of common stock at $1.50 per share. The company states that the proceeds from this stock sale are expected to extend its cash runway into the fourth quarter of 2026, giving it more time to fund operations and development plans without needing additional financing in the near term. The transaction and related details were also highlighted in a press release filed as an exhibit.
Ocugen, Inc. entered into an underwriting agreement with Oppenheimer & Co. Inc. to sell 15,000,000 shares of common stock at $1.50 per share in an underwritten public offering. The offering is expected to close on or about January 22, 2026, subject to customary closing conditions.
Ocugen expects to receive approximately $20.8 million in net proceeds after underwriting discounts, commissions and estimated expenses. The company plans to use the cash for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The shares are being issued under an effective Form S-3 shelf registration and a January 20, 2026 prospectus supplement.